Clinical Trials Market in US 2025-2029

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,500	166 Pages	TechNavio	February, 2025	INF19584749

Best Price Guarantee
Price	from $2,500
Length	166 Pages
Publisher	TechNavio
Published Date	February, 2025
SKU	INF19584749

Clinical Trials Market In US 2025-2029

The clinical trials market in US is forecasted to grow by USD 6.5 billion during 2024-2029, accelerating at a CAGR of 5.3% during the forecast period. The report on the clinical trials market in US provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rise in number of clinical trials of drugs, rise in adoption of artificial intelligence (AI)-based tools for drug delivery, and growing demand for personalized medicine and targeted therapies.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's clinical trials market in US is segmented as below:

By Type

Phase III
Phase I
Phase II
Phase IV

By Service Type

Interventional studies
Observational studies
Expanded access studies

By Indication

Oncology
CNS
Autoimmune/inflammation
Others

By Geographical Landscape

North America

This study identifies the advancement in technology and scientific research as one of the prime reasons driving the clinical trials market in US growth during the next few years. Also, rise in outsourcing of clinical trial process and growing investment in healthcare and pharmaceutical industries will lead to sizable demand in the market.

The report on the clinical trials market in US covers the following areas:

Clinical Trials Market in US sizing
Clinical Trials Market in US forecast
Clinical Trials Market in US industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading clinical trials market in US vendors that include Accell Clinical Research LLC, Apex Medical Research Inc., Caidya, Charles River Laboratories International Inc., Clario, Clinipace Inc., CTI Clinical Trial and Consulting Inc., Eli Lilly and Co., ICON PLC, IQVIA Holdings Inc., Laboratory Corp. of America Holdings, Medpace Holdings Inc., Novartis AG, Novo Nordisk AS, Parexel International Corp., Pfizer Inc., Sanofi SA, Syneos Health, Thermo Fisher Scientific Inc., and WuXi AppTec Co. Ltd.. Also, the clinical trials market in US analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

1 Executive Summary: 1.1 Market overview; Executive Summary - Chart on Market Overview; Executive Summary - Data Table on Market Overview; Executive Summary - Chart on Country Market Characteristics; Executive Summary - Chart on Market Segmentation by Type; Executive Summary - Chart on Market Segmentation by Service Type; Executive Summary - Chart on Market Segmentation by Indication; Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis: 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; 2.2 Criticality of inputs and Factors of differentiation; Overview on criticality of inputs and factors of differentiation; 2.3 Factors of disruption; Overview on factors of disruption; 2.4 Impact of drivers and challenges; Impact of drivers and challenges in 2024 and 2029
3 Market Landscape: 3.1 Market ecosystem; Parent Market; Data Table on - Parent Market; 3.2 Market characteristics; Market characteristics analysis; 3.3 Value chain analysis; Value chain analysis
4 Market Sizing: 4.1 Market definition; Offerings of companies included in the market definition; 4.2 Market segment analysis; Market segments; 4.3 Market size 2024; 4.4 Market outlook: Forecast for 2024-2029; Chart on US - Market size and forecast 2024-2029 ($ billion); Data Table on US - Market size and forecast 2024-2029 ($ billion); Chart on US: Year-over-year growth 2024-2029 (%); Data Table on US: Year-over-year growth 2024-2029 (%)
5 Historic Market Size: 5.1 Clinical Trials Market in US 2019 - 2023; Historic Market Size - Data Table on Clinical Trials Market in US 2019 - 2023 ($ billion); 5.2 Type segment analysis 2019 - 2023; Historic Market Size - Type Segment 2019 - 2023 ($ billion); 5.3 Service Type segment analysis 2019 - 2023; Historic Market Size - Service Type Segment 2019 - 2023 ($ billion); 5.4 Indication segment analysis 2019 - 2023; Historic Market Size - Indication Segment 2019 - 2023 ($ billion)
6 Qualitative Analysis: 6.1 AI Impact on Clinical Trials Market in US
7 Five Forces Analysis: 7.1 Five forces summary; Five forces analysis - Comparison between 2024 and 2029; 7.2 Bargaining power of buyers; Bargaining power of buyers - Impact of key factors 2024 and 2029; 7.3 Bargaining power of suppliers; Bargaining power of suppliers - Impact of key factors in 2024 and 2029; 7.4 Threat of new entrants; Threat of new entrants - Impact of key factors in 2024 and 2029; 7.5 Threat of substitutes; Threat of substitutes - Impact of key factors in 2024 and 2029; 7.6 Threat of rivalry; Threat of rivalry - Impact of key factors in 2024 and 2029; 7.7 Market condition; Chart on Market condition - Five forces 2024 and 2029
8 Market Segmentation by Type: 8.1 Market segments; Chart on Type - Market share 2024-2029 (%); Data Table on Type - Market share 2024-2029 (%); 8.2 Comparison by Type; Chart on Comparison by Type; Data Table on Comparison by Type; 8.3 Phase III - Market size and forecast 2024-2029; Chart on Phase III - Market size and forecast 2024-2029 ($ billion); Data Table on Phase III - Market size and forecast 2024-2029 ($ billion); Chart on Phase III - Year-over-year growth 2024-2029 (%); Data Table on Phase III - Year-over-year growth 2024-2029 (%); 8.4 Phase I - Market size and forecast 2024-2029; Chart on Phase I - Market size and forecast 2024-2029 ($ billion); Data Table on Phase I - Market size and forecast 2024-2029 ($ billion); Chart on Phase I - Year-over-year growth 2024-2029 (%); Data Table on Phase I - Year-over-year growth 2024-2029 (%); 8.5 Phase II - Market size and forecast 2024-2029; Chart on Phase II - Market size and forecast 2024-2029 ($ billion); Data Table on Phase II - Market size and forecast 2024-2029 ($ billion); Chart on Phase II - Year-over-year growth 2024-2029 (%); Data Table on Phase II - Year-over-year growth 2024-2029 (%); 8.6 Phase IV - Market size and forecast 2024-2029; Chart on Phase IV - Market size and forecast 2024-2029 ($ billion); Data Table on Phase IV - Market size and forecast 2024-2029 ($ billion); Chart on Phase IV - Year-over-year growth 2024-2029 (%); Data Table on Phase IV - Year-over-year growth 2024-2029 (%); 8.7 Market opportunity by Type; Market opportunity by Type ($ billion); Data Table on Market opportunity by Type ($ billion)
9 Market Segmentation by Service Type: 9.1 Market segments; Chart on Service Type - Market share 2024-2029 (%); Data Table on Service Type - Market share 2024-2029 (%); 9.2 Comparison by Service Type; Chart on Comparison by Service Type; Data Table on Comparison by Service Type; 9.3 Interventional studies - Market size and forecast 2024-2029; Chart on Interventional studies - Market size and forecast 2024-2029 ($ billion); Data Table on Interventional studies - Market size and forecast 2024-2029 ($ billion); Chart on Interventional studies - Year-over-year growth 2024-2029 (%); Data Table on Interventional studies - Year-over-year growth 2024-2029 (%); 9.4 Observational studies - Market size and forecast 2024-2029; Chart on Observational studies - Market size and forecast 2024-2029 ($ billion); Data Table on Observational studies - Market size and forecast 2024-2029 ($ billion); Chart on Observational studies - Year-over-year growth 2024-2029 (%); Data Table on Observational studies - Year-over-year growth 2024-2029 (%); 9.5 Expanded access studies - Market size and forecast 2024-2029; Chart on Expanded access studies - Market size and forecast 2024-2029 ($ billion); Data Table on Expanded access studies - Market size and forecast 2024-2029 ($ billion); Chart on Expanded access studies - Year-over-year growth 2024-2029 (%); Data Table on Expanded access studies - Year-over-year growth 2024-2029 (%); 9.6 Market opportunity by Service Type; Market opportunity by Service Type ($ billion); Data Table on Market opportunity by Service Type ($ billion)
10 Market Segmentation by Indication: 10.1 Market segments; Chart on Indication - Market share 2024-2029 (%); Data Table on Indication - Market share 2024-2029 (%); 10.2 Comparison by Indication; Chart on Comparison by Indication; Data Table on Comparison by Indication; 10.3 Oncology - Market size and forecast 2024-2029; Chart on Oncology - Market size and forecast 2024-2029 ($ billion); Data Table on Oncology - Market size and forecast 2024-2029 ($ billion); Chart on Oncology - Year-over-year growth 2024-2029 (%); Data Table on Oncology - Year-over-year growth 2024-2029 (%); 10.4 CNS - Market size and forecast 2024-2029; Chart on CNS - Market size and forecast 2024-2029 ($ billion); Data Table on CNS - Market size and forecast 2024-2029 ($ billion); Chart on CNS - Year-over-year growth 2024-2029 (%); Data Table on CNS - Year-over-year growth 2024-2029 (%); 10.5 Autoimmune/inflammation - Market size and forecast 2024-2029; Chart on Autoimmune/inflammation - Market size and forecast 2024-2029 ($ billion); Data Table on Autoimmune/inflammation - Market size and forecast 2024-2029 ($ billion); Chart on Autoimmune/inflammation - Year-over-year growth 2024-2029 (%); Data Table on Autoimmune/inflammation - Year-over-year growth 2024-2029 (%); 10.6 Others - Market size and forecast 2024-2029; Chart on Others - Market size and forecast 2024-2029 ($ billion); Data Table on Others - Market size and forecast 2024-2029 ($ billion); Chart on Others - Year-over-year growth 2024-2029 (%); Data Table on Others - Year-over-year growth 2024-2029 (%); 10.7 Market opportunity by Indication; Market opportunity by Indication ($ billion); Data Table on Market opportunity by Indication ($ billion)
11 Customer Landscape: 11.1 Customer landscape overview; Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Drivers, Challenges, and Opportunity/Restraints: 12.1 Market drivers; 12.2 Market challenges; 12.3 Impact of drivers and challenges; Impact of drivers and challenges in 2024 and 2029; 12.4 Market opportunities/restraints
13 Competitive Landscape: 13.1 Overview; 13.2 Competitive Landscape; Overview on criticality of inputs and factors of differentiation; 13.3 Landscape disruption; Overview on factors of disruption; 13.4 Industry risks; Impact of key risks on business
14 Competitive Analysis: 14.1 Companies profiled; Companies covered; 14.2 Company ranking index; Company ranking index; 14.3 Market positioning of companies; Matrix on companies position and classification; 14.4 Accell Clinical Research LLC; Accell Clinical Research LLC - Overview; Accell Clinical Research LLC - Product / Service; Accell Clinical Research LLC - Key offerings; SWOT; 14.5 Caidya; Caidya - Overview; Caidya - Product / Service; Caidya - Key offerings; SWOT; 14.6 Charles River Laboratories International Inc.; Charles River Laboratories International Inc. - Overview; Charles River Laboratories International Inc. - Business segments; Charles River Laboratories International Inc. - Key offerings; Charles River Laboratories International Inc. - Segment focus; SWOT; 14.7 Clinipace Inc.; Clinipace Inc. - Overview; Clinipace Inc. - Product / Service; Clinipace Inc. - Key offerings; SWOT; 14.8 CTI Clinical Trial and Consulting Inc.; CTI Clinical Trial and Consulting Inc. - Overview; CTI Clinical Trial and Consulting Inc. - Product / Service; CTI Clinical Trial and Consulting Inc. - Key offerings; SWOT; 14.9 Eli Lilly and Co.; Eli Lilly and Co. - Overview; Eli Lilly and Co. - Product / Service; Eli Lilly and Co. - Key offerings; SWOT; 14.10 ICON plc; ICON plc - Overview; ICON plc - Product / Service; ICON plc - Key offerings; SWOT; 14.11 IQVIA Holdings Inc.; IQVIA Holdings Inc. - Overview; IQVIA Holdings Inc. - Business segments; IQVIA Holdings Inc. - Key offerings; IQVIA Holdings Inc. - Segment focus; SWOT; 14.12 Laboratory Corp. of America Holdings; Laboratory Corp. of America Holdings - Overview; Laboratory Corp. of America Holdings - Business segments; Laboratory Corp. of America Holdings - Key news; Laboratory Corp. of America Holdings - Key offerings; Laboratory Corp. of America Holdings - Segment focus; SWOT; 14.13 Medpace Holdings Inc.; Medpace Holdings Inc. - Overview; Medpace Holdings Inc. - Product / Service; Medpace Holdings Inc. - Key offerings; SWOT; 14.14 Parexel International Corp.; Parexel International Corp. - Overview; Parexel International Corp. - Product / Service; Parexel International Corp. - Key offerings; SWOT; 14.15 Pfizer Inc.; Pfizer Inc. - Overview; Pfizer Inc. - Product / Service; Pfizer Inc. - Key news; Pfizer Inc. - Key offerings; SWOT; 14.16 Sanofi SA; Sanofi SA - Overview; Sanofi SA - Business segments; Sanofi SA - Key news; Sanofi SA - Key offerings; Sanofi SA - Segment focus; SWOT; 14.17 Syneos Health; Syneos Health - Overview; Syneos Health - Product / Service; Syneos Health - Key offerings; SWOT; 14.18 Thermo Fisher Scientific Inc.; Thermo Fisher Scientific Inc. - Overview; Thermo Fisher Scientific Inc. - Business segments; Thermo Fisher Scientific Inc. - Key news; Thermo Fisher Scientific Inc. - Key offerings; Thermo Fisher Scientific Inc. - Segment focus; SWOT
15 Appendix: 15.1 Scope of the report; 15.2 Inclusions and exclusions checklist; Inclusions checklist; Exclusions checklist; 15.3 Currency conversion rates for US$; Currency conversion rates for US$; 15.4 Research methodology; Research methodology; 15.5 Data procurement; Information sources; 15.6 Data validation; Data validation; 15.7 Validation techniques employed for market sizing; Validation techniques employed for market sizing; 15.8 Data synthesis; Data synthesis; 15.9 360 degree market analysis; 360 degree market analysis; 15.10 List of abbreviations; List of abbreviations
Exhibits:: Exhibits1: Executive Summary - Chart on Market Overview; Exhibits2: Executive Summary - Data Table on Market Overview; Exhibits3: Executive Summary - Chart on Country Market Characteristics; Exhibits4: Executive Summary - Chart on Market Segmentation by Type; Exhibits5: Executive Summary - Chart on Market Segmentation by Service Type; Exhibits6: Executive Summary - Chart on Market Segmentation by Indication; Exhibits7: Executive Summary - Chart on Company Market Positioning; Exhibits8: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Exhibits9: Overview on criticality of inputs and factors of differentiation; Exhibits10: Overview on factors of disruption; Exhibits11: Impact of drivers and challenges in 2024 and 2029; Exhibits12: Parent Market; Exhibits13: Data Table on - Parent Market; Exhibits14: Market characteristics analysis; Exhibits15: Value chain analysis; Exhibits16: Offerings of companies included in the market definition; Exhibits17: Market segments; Exhibits18: Chart on US - Market size and forecast 2024-2029 ($ billion); Exhibits19: Data Table on US - Market size and forecast 2024-2029 ($ billion); Exhibits20: Chart on US: Year-over-year growth 2024-2029 (%); Exhibits21: Data Table on US: Year-over-year growth 2024-2029 (%); Exhibits22: Historic Market Size - Data Table on Clinical Trials Market in US 2019 - 2023 ($ billion); Exhibits23: Historic Market Size - Type Segment 2019 - 2023 ($ billion); Exhibits24: Historic Market Size - Service Type Segment 2019 - 2023 ($ billion); Exhibits25: Historic Market Size - Indication Segment 2019 - 2023 ($ billion); Exhibits26: Five forces analysis - Comparison between 2024 and 2029; Exhibits27: Bargaining power of buyers - Impact of key factors 2024 and 2029; Exhibits28: Bargaining power of suppliers - Impact of key factors in 2024 and 2029; Exhibits29: Threat of new entrants - Impact of key factors in 2024 and 2029; Exhibits30: Threat of substitutes - Impact of key factors in 2024 and 2029; Exhibits31: Threat of rivalry - Impact of key factors in 2024 and 2029; Exhibits32: Chart on Market condition - Five forces 2024 and 2029; Exhibits33: Chart on Type - Market share 2024-2029 (%); Exhibits34: Data Table on Type - Market share 2024-2029 (%); Exhibits35: Chart on Comparison by Type; Exhibits36: Data Table on Comparison by Type; Exhibits37: Chart on Phase III - Market size and forecast 2024-2029 ($ billion); Exhibits38: Data Table on Phase III - Market size and forecast 2024-2029 ($ billion); Exhibits39: Chart on Phase III - Year-over-year growth 2024-2029 (%); Exhibits40: Data Table on Phase III - Year-over-year growth 2024-2029 (%); Exhibits41: Chart on Phase I - Market size and forecast 2024-2029 ($ billion); Exhibits42: Data Table on Phase I - Market size and forecast 2024-2029 ($ billion); Exhibits43: Chart on Phase I - Year-over-year growth 2024-2029 (%); Exhibits44: Data Table on Phase I - Year-over-year growth 2024-2029 (%); Exhibits45: Chart on Phase II - Market size and forecast 2024-2029 ($ billion); Exhibits46: Data Table on Phase II - Market size and forecast 2024-2029 ($ billion); Exhibits47: Chart on Phase II - Year-over-year growth 2024-2029 (%); Exhibits48: Data Table on Phase II - Year-over-year growth 2024-2029 (%); Exhibits49: Chart on Phase IV - Market size and forecast 2024-2029 ($ billion); Exhibits50: Data Table on Phase IV - Market size and forecast 2024-2029 ($ billion); Exhibits51: Chart on Phase IV - Year-over-year growth 2024-2029 (%); Exhibits52: Data Table on Phase IV - Year-over-year growth 2024-2029 (%); Exhibits53: Market opportunity by Type ($ billion); Exhibits54: Data Table on Market opportunity by Type ($ billion); Exhibits55: Chart on Service Type - Market share 2024-2029 (%); Exhibits56: Data Table on Service Type - Market share 2024-2029 (%); Exhibits57: Chart on Comparison by Service Type; Exhibits58: Data Table on Comparison by Service Type; Exhibits59: Chart on Interventional studies - Market size and forecast 2024-2029 ($ billion); Exhibits60: Data Table on Interventional studies - Market size and forecast 2024-2029 ($ billion); Exhibits61: Chart on Interventional studies - Year-over-year growth 2024-2029 (%); Exhibits62: Data Table on Interventional studies - Year-over-year growth 2024-2029 (%); Exhibits63: Chart on Observational studies - Market size and forecast 2024-2029 ($ billion); Exhibits64: Data Table on Observational studies - Market size and forecast 2024-2029 ($ billion); Exhibits65: Chart on Observational studies - Year-over-year growth 2024-2029 (%); Exhibits66: Data Table on Observational studies - Year-over-year growth 2024-2029 (%); Exhibits67: Chart on Expanded access studies - Market size and forecast 2024-2029 ($ billion); Exhibits68: Data Table on Expanded access studies - Market size and forecast 2024-2029 ($ billion); Exhibits69: Chart on Expanded access studies - Year-over-year growth 2024-2029 (%); Exhibits70: Data Table on Expanded access studies - Year-over-year growth 2024-2029 (%); Exhibits71: Market opportunity by Service Type ($ billion); Exhibits72: Data Table on Market opportunity by Service Type ($ billion); Exhibits73: Chart on Indication - Market share 2024-2029 (%); Exhibits74: Data Table on Indication - Market share 2024-2029 (%); Exhibits75: Chart on Comparison by Indication; Exhibits76: Data Table on Comparison by Indication; Exhibits77: Chart on Oncology - Market size and forecast 2024-2029 ($ billion); Exhibits78: Data Table on Oncology - Market size and forecast 2024-2029 ($ billion); Exhibits79: Chart on Oncology - Year-over-year growth 2024-2029 (%); Exhibits80: Data Table on Oncology - Year-over-year growth 2024-2029 (%); Exhibits81: Chart on CNS - Market size and forecast 2024-2029 ($ billion); Exhibits82: Data Table on CNS - Market size and forecast 2024-2029 ($ billion); Exhibits83: Chart on CNS - Year-over-year growth 2024-2029 (%); Exhibits84: Data Table on CNS - Year-over-year growth 2024-2029 (%); Exhibits85: Chart on Autoimmune/inflammation - Market size and forecast 2024-2029 ($ billion); Exhibits86: Data Table on Autoimmune/inflammation - Market size and forecast 2024-2029 ($ billion); Exhibits87: Chart on Autoimmune/inflammation - Year-over-year growth 2024-2029 (%); Exhibits88: Data Table on Autoimmune/inflammation - Year-over-year growth 2024-2029 (%); Exhibits89: Chart on Others - Market size and forecast 2024-2029 ($ billion); Exhibits90: Data Table on Others - Market size and forecast 2024-2029 ($ billion); Exhibits91: Chart on Others - Year-over-year growth 2024-2029 (%); Exhibits92: Data Table on Others - Year-over-year growth 2024-2029 (%); Exhibits93: Market opportunity by Indication ($ billion); Exhibits94: Data Table on Market opportunity by Indication ($ billion); Exhibits95: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Exhibits96: Impact of drivers and challenges in 2024 and 2029; Exhibits97: Overview on criticality of inputs and factors of differentiation; Exhibits98: Overview on factors of disruption; Exhibits99: Impact of key risks on business; Exhibits100: Companies covered; Exhibits101: Company ranking index; Exhibits102: Matrix on companies position and classification; Exhibits103: Accell Clinical Research LLC - Overview; Exhibits104: Accell Clinical Research LLC - Product / Service; Exhibits105: Accell Clinical Research LLC - Key offerings; Exhibits106: SWOT; Exhibits107: Caidya - Overview; Exhibits108: Caidya - Product / Service; Exhibits109: Caidya - Key offerings; Exhibits110: SWOT; Exhibits111: Charles River Laboratories International Inc. - Overview; Exhibits112: Charles River Laboratories International Inc. - Business segments; Exhibits113: Charles River Laboratories International Inc. - Key offerings; Exhibits114: Charles River Laboratories International Inc. - Segment focus; Exhibits115: SWOT; Exhibits116: Clinipace Inc. - Overview; Exhibits117: Clinipace Inc. - Product / Service; Exhibits118: Clinipace Inc. - Key offerings; Exhibits119: SWOT; Exhibits120: CTI Clinical Trial and Consulting Inc. - Overview; Exhibits121: CTI Clinical Trial and Consulting Inc. - Product / Service; Exhibits122: CTI Clinical Trial and Consulting Inc. - Key offerings; Exhibits123: SWOT; Exhibits124: Eli Lilly and Co. - Overview; Exhibits125: Eli Lilly and Co. - Product / Service; Exhibits126: Eli Lilly and Co. - Key offerings; Exhibits127: SWOT; Exhibits128: ICON plc - Overview; Exhibits129: ICON plc - Product / Service; Exhibits130: ICON plc - Key offerings; Exhibits131: SWOT; Exhibits132: IQVIA Holdings Inc. - Overview; Exhibits133: IQVIA Holdings Inc. - Business segments; Exhibits134: IQVIA Holdings Inc. - Key offerings; Exhibits135: IQVIA Holdings Inc. - Segment focus; Exhibits136: SWOT; Exhibits137: Laboratory Corp. of America Holdings - Overview; Exhibits138: Laboratory Corp. of America Holdings - Business segments; Exhibits139: Laboratory Corp. of America Holdings - Key news; Exhibits140: Laboratory Corp. of America Holdings - Key offerings; Exhibits141: Laboratory Corp. of America Holdings - Segment focus; Exhibits142: SWOT; Exhibits143: Medpace Holdings Inc. - Overview; Exhibits144: Medpace Holdings Inc. - Product / Service; Exhibits145: Medpace Holdings Inc. - Key offerings; Exhibits146: SWOT; Exhibits147: Parexel International Corp. - Overview; Exhibits148: Parexel International Corp. - Product / Service; Exhibits149: Parexel International Corp. - Key offerings; Exhibits150: SWOT; Exhibits151: Pfizer Inc. - Overview; Exhibits152: Pfizer Inc. - Product / Service; Exhibits153: Pfizer Inc. - Key news; Exhibits154: Pfizer Inc. - Key offerings; Exhibits155: SWOT; Exhibits156: Sanofi SA - Overview; Exhibits157: Sanofi SA - Business segments; Exhibits158: Sanofi SA - Key news; Exhibits159: Sanofi SA - Key offerings; Exhibits160: Sanofi SA - Segment focus; Exhibits161: SWOT; Exhibits162: Syneos Health - Overview; Exhibits163: Syneos Health - Product / Service; Exhibits164: Syneos Health - Key offerings; Exhibits165: SWOT; Exhibits166: Thermo Fisher Scientific Inc. - Overview; Exhibits167: Thermo Fisher Scientific Inc. - Business segments; Exhibits168: Thermo Fisher Scientific Inc. - Key news; Exhibits169: Thermo Fisher Scientific Inc. - Key offerings; Exhibits170: Thermo Fisher Scientific Inc. - Segment focus; Exhibits171: SWOT; Exhibits172: Inclusions checklist; Exhibits173: Exclusions checklist; Exhibits174: Currency conversion rates for US$; Exhibits175: Research methodology; Exhibits176: Information sources; Exhibits177: Data validation; Exhibits178: Validation techniques employed for market sizing; Exhibits179: Data synthesis; Exhibits180: 360 degree market analysis; Exhibits181: List of abbreviations